CHRONIC HEPATITIS B VIRUS INFECTION
Clinical trials for CHRONIC HEPATITIS B VIRUS INFECTION explained in plain language.
Never miss a new study
Get alerted when new CHRONIC HEPATITIS B VIRUS INFECTION trials appear
Sign up with your email to follow new studies for CHRONIC HEPATITIS B VIRUS INFECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental hepatitis b drug shows promise in early trial
Disease control TerminatedThis Phase 2 trial tested an experimental drug called ARC-520 in 58 people with chronic hepatitis B who were already taking standard antivirals. The goal was to see if ARC-520 could further lower hepatitis B surface antigen levels, a marker of the virus. The study was terminated …
Matched conditions: CHRONIC HEPATITIS B VIRUS INFECTION
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental hepatitis b drug shows promise in early trial
Disease control TerminatedThis study tested a new drug called ARC-520 in 79 people with chronic hepatitis B. Some participants received ARC-520 alone, while others got it combined with standard treatments like entecavir or tenofovir. The goal was to see if ARC-520 could lower hepatitis B surface antigen l…
Matched conditions: CHRONIC HEPATITIS B VIRUS INFECTION
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental hepatitis b drug combo shows promise but study halted early
Disease control TerminatedThis study tested an experimental drug called ARC-520 given alongside standard hepatitis B medications (entecavir or tenofovir) in 12 people with chronic hepatitis B. Participants received 9 doses of ARC-520 over 36 weeks to see if it could safely lower hepatitis B virus levels. …
Matched conditions: CHRONIC HEPATITIS B VIRUS INFECTION
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental hepatitis b drug trial halted midway
Disease control TerminatedThis study tested an experimental drug called ARC-520 in 32 adults with chronic hepatitis B who were already taking antiviral medications (entecavir or tenofovir). The goal was to see if adding ARC-520 could lower hepatitis B surface antigen levels more than placebo. The trial wa…
Matched conditions: CHRONIC HEPATITIS B VIRUS INFECTION
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC